Inside the WHO's Pathogen Access System: The Global Debate Over Biosecurity and Vaccine Equity

In May 2025, the global health community celebrated a historic milestone: the adoption of the world's first Pandemic Agreement. Designed to prevent the catastrophic failures of the COVID-19 era, the treaty established broad principles for international cooperation. But the agreement carried a massive asterisk. The most critical mechanism—the specific rules governing how countries share dangerous viruses and who gets the resulting vaccines—was left blank.

That missing piece is the Pathogen Access and Benefit-Sharing (PABS) system. It is the engine that will determine how the world responds to the next outbreak. Currently, the Intergovernmental Working Group (IGWG) is locked in intensive negotiations in Geneva, with a final deadline pushed to May 2027 to resolve the standoff.[2]

The debate over PABS represents a fundamental rewiring of the global health order. For decades, the genetic sequence of a newly discovered virus was treated as a global public good. Scientists uploaded the data to open databases, and pharmaceutical companies downloaded it to design tests, therapeutics, and vaccines without any binding obligations to the countries that provided the data.[3]

However, the COVID-19 pandemic shattered trust in that frictionless system. When South African and Botswana scientists identified the Omicron variant, they immediately shared the genetic data with the world. In return, they were hit with devastating travel bans, while their populations waited months for the updated vaccines developed using their own genomic sequencing.[1][3]

"The PABS annex is the last piece of the puzzle," noted WHO Director-General Dr. Tedros Adhanom Ghebreyesus, emphasizing that the next pandemic is a matter of when, not if. The goal is to create a legally binding framework that ensures both the rapid sharing of pathogens and the equitable distribution of the medical benefits they yield.

Under the proposed PABS framework, when a country identifies a novel pathogen with pandemic potential, it would upload the genetic sequence data to a WHO-coordinated network. In exchange, pharmaceutical manufacturers utilizing that data would be required to commit a percentage—currently targeted at 20%—of their real-time production of vaccines, therapeutics, and diagnostics to the WHO for equitable global distribution.

This transactional model is rooted in a broader shift in international law. Increasingly, countries are applying the Nagoya Protocol—a 2010 biodiversity treaty—to microscopic threats. Under this framework, pathogens are viewed as sovereign genetic resources, meaning the country where a virus emerges has rights over how its genetic code is commercialized.

A bloc of over 100 low- and middle-income countries (LMICs) is leveraging this legal standing to demand mandatory benefit-sharing. They argue that the era of extracting biological data from the Global South without guaranteed access to the resulting medical breakthroughs is over. For these nations, PABS is a necessary corrective to historical inequities, and they have threatened to withhold pathogen samples if their demands are not met.

Conversely, high-income nations and the pharmaceutical industry warn that an overly rigid PABS system could backfire catastrophically. They argue that placing pathogen sequence data behind a transactional gateway will slow down the scientific response during the critical early days of an outbreak, when every hour counts.[2]

Industry advocates maintain that the record-breaking development of mRNA vaccines in 2020 was only possible because genetic data was shared openly and without legal friction. They favor a system where data remains freely accessible, with benefit-sharing handled through voluntary commitments, tiered pricing, and collaborative technology transfers rather than hard production quotas.[1]

Global health security experts find themselves caught in the middle. Their primary concern is maintaining a pathogen-agnostic early warning system. If countries delay sharing data while lawyers negotiate access terms, a localized outbreak could easily spiral into an unstoppable global crisis.[3]

To bridge the divide, negotiators are exploring hybrid models. One proposal involves a tiered system where academic researchers maintain open access to data, while commercial entities trigger benefit-sharing obligations only when they bring a profitable product to market.

Another avenue of compromise is the establishment of a dedicated financing mechanism. By pooling international funds to support laboratory capacity, genomic sequencing, and local manufacturing in LMICs, the system could provide immediate non-monetary benefits to provider countries, easing the pressure on direct vaccine quotas.[1]

As the IGWG prepares for its seventh meeting in July 2026, the stakes could not be higher. The technical complexity of tracking digital sequence information across global supply chains is matched only by the political difficulty of balancing national sovereignty with collective security.

Ultimately, the PABS negotiations are about more than just the next virus; they are about establishing a baseline of trust. If the WHO can successfully engineer a system that protects both scientific innovation and human equity, it will not just close the biosecurity divide—it will build a far more resilient architecture for the future of global health.[3]